Lilly completes Verve Therapeutics acquisition for cardiovascular treatments Jul 25, 2025 08:50AM
Increasing unusual option volume: VERV OPEN UPXI DDD ALGM TRU GPRO DNUT CDTX Jul 24, 2025 10:51AM
Lilly tender offer for Verve expires with 55.7% of shares tendered Jul 24, 2025 08:01AM
BMO Capital Downgrades Verve Therapeutics (VERV) to Market Perform Jun 26, 2025 04:34PM
Eli Lilly and Verve's gene-editing M&A deal 'an important milestone' - Citizens JMP Jun 18, 2025 04:45AM


Jun 18, 2025 02:10AM Jefferies Downgrades Verve Therapeutics (VERV) to Hold
Jun 17, 2025 04:17PM LifeSci Capital Downgrades Verve Therapeutics (VERV) to Market Perform
Jun 17, 2025 11:22AM BMO Capital sees 70% chance Verve Therapeutics (VERV) receives CVR payout
Jun 17, 2025 06:46AM Eli Lilly & Co. (LLY) to acquire Verve Therapeutics (VERV) for $10.50/sh Cash plus CVR
Jun 16, 2025 07:35PM Eli Lilly & Co. (LLY) In Advanced Talks To Buy Verve For Up To $1.3bln- FT
May 15, 2025 06:44AM Canaccord Genuity Reiterates Buy Rating on Verve Therapeutics (VERV)
May 14, 2025 04:17PM Verve Therapeutics, Inc. (VERV) Tops Q1 EPS by 30c
Apr 15, 2025 08:51AM BMO Capital Reiterates Outperform Rating on Verve Therapeutics (VERV), PT $30
Apr 15, 2025 07:18AM Verve Therapeutics (VERV) PT Raised to $24 at Guggenheim
Apr 15, 2025 07:10AM William Blair on Verve Therapeutics (VERV): 'Heart-2 First Look: Reads as a Clear Win With Clean VERVE-102 Safety'
Apr 15, 2025 06:36AM Verve Therapeutics (VERV) PT Raised to $39 at Canaccord Genuity
Apr 15, 2025 06:33AM Cantor Fitzgerald Upgrades Verve Therapeutics (VERV) to Overweight, 'We're Impressed by VERVE-102'
Apr 15, 2025 06:19AM Verve Therapeutics (VERV) Surges 10pct Premarket on Cantor Upgrade, Bullish Commentary, Updated News
Apr 15, 2025 06:09AM Goldman Comments on Verve Therapeutics (VERV)
Apr 15, 2025 06:06AM Jefferies Reiterates Buy Rating on Verve Therapeutics (VERV)
Apr 14, 2025 07:00AM Verve Therapeutics (VERV) Announces Positive Initial Data from the Heart-2 Phase 1b Trial of VERVE-102
Apr 11, 2025 07:00AM Verve Therapeutics (VERV) Receives U.S. FDA Fast Track Designation for VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9
Mar 25, 2025 09:10AM BMO Capital Sees Upside Potential for Verve Therapeutics (VERV)
Mar 25, 2025 06:38AM Canaccord Genuity Reiterates Buy Rating on Verve Therapeutics (VERV)
Mar 24, 2025 07:00AM Verve Therapeutics (VERV) Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-102
Feb 28, 2025 08:08AM Verve Therapeutics (VERV) PT Raised to $15 at H.C. Wainwright
Feb 27, 2025 08:09AM Verve Therapeutics, Inc. (VERV) Tops Q4 EPS by 10c
Jan 7, 2025 05:37PM Kuehn Law Encourages Investors of Verve Therapeutics, Inc. to Contact Law Firm
Dec 19, 2024 09:42AM Stifel Names Top Picks in Biotechnology 2025 Outlook Note
Dec 5, 2024 07:00AM BioGene Therapeutics Welcomes Ex Pfizer and Moderna Senior Leadership Dr. Barry Ticho
Nov 6, 2024 06:49AM Verve Therapeutics (VERV) PT Lowered to $14 at H.C. Wainwright
Aug 9, 2024 06:29AM Verve Therapeutics (VERV) PT Lowered to $20 at RBC Capital
Jun 28, 2024 07:01AM Verve Therapeutics (VERV) Appoints Nia Tatsis and Jodie Morrison to its Board